In one of those trials, treatment with the ETAR antagonist Atrasentan led to an improvement in microvascular function in early coronary atherosclerosis, monitored by examination of endothelium-independent coronary flow reserve [33]. Here, EDNRA is linked to coronary atherosclerosis.